Terumo Corp. (TYO:4543) said yesterday it tapped Rob DeRyke as its new CV group prez & CEO, effective April 1, 2017, succeeding a retiring Mark Sutter.
Prior to his appointment, DeRyke operated as Terumo CV group electromechanical systems division prez, the company said.
“Under his leadership, Rob brought stability and improved profitability to the business,” Terumo Corp prez & CEO Shinjiro Sato said in a press release.
DeRyke joined Terumo in 2012 as corporate quality VP, and has 25 years of experience in med device and pharmaceuticals, the company said. He has previously held positions at Baxter (NYSE:BAX), Hospira and Thermo Fisher (NYSE:TMO).
“We have a strong foundation of talent, technologies, and systems to build on as we deliver long-term value to our customers and their patients,” DeRyke said in a prepared statement.
MedPlast said today it tapped Brain King as its new CEO and board member, effective May 1, 2017.
The Tempe, Ariz.-based company said the appointment is part of a planned leadership transition, with King taking over for Harold Faig, who will continue to serve on the company’s board.
“This is a transition that I have been planning with the Board for some time. I am very pleased that we have recruited a leader of Brian’s caliber to lead MedPlast forward. His industry expertise, global operations experience and commitment to quality will be invaluable to completing the next step in our long-term plan of establishing MedPlast as the first end-to-end services provider in the medical device industry,” Faig said in a prepared statement.
King has previously held executive positions with both Covidien and Johnson & Johnson‘s (NYSE:JNJ) DePuy Synthes biz, the company said.
“I am excited to join MedPlast and build on the strong foundation that Harold and his team have created at the company. Having worked in the medical device industry for many years, I see a tremendous need and opportunity to create an end-to-end services provider. MedPlast has all of the key components, particularly the expertise, range of capabilities and high-quality standards, to become a differentiated services partner to medical device companies,” King said in a prepared release.
Varian Medical names Bischoping Jr as new CFO
Varian Medical (NYSE:VAR) said this week it named Gary Bischoping Jr, previously of Dell Technologies, as its new chief financial officer, effective May 8.
Bischoping will replace Elisha Finney, who will retire after 29 years at the company, with more than 18 hears served as the company’s initial CFO.
“Gary brings broad financial experience to Varian that will enable him to serve our management team and the company as a very effective business partner who will help to drive our ongoing growth strategy,” prez & CEO Dow Wilson, President and CEO of Varian Medical Systems.
Bischoping spent 17 years with dell, serving most recently as Dell client services group chief financial officer, according to Varian Medical.
Second Sight founder named National Academy of Inventors fellow
Second Sight Medical (NSDQ:EYES) said this week that its chair Dr. Robert Greenberg will be inducted as a National Academy of Inventors Fellow.
The induction took place at the 6th Annual Conference of the National Academy of Inventors at the John F. Kennedy Presidential Library & Museum in Boston.
“On behalf of the Board of Directors and the entire team at Second Sight, we congratulate Bob for his distinguished and profound contributions to science, technology, and medicine, which have advanced our understanding of the tremendous potential of technology to restore vision and enabled blind individuals with Retinitis Pigmentosa to regain some useful vision,” prez & CEO Will McGuire said in a press release.
The retinal prosthesis manufacturer said that the honor is the highest professional distinction which can be accorded to investors who’s creations have made a tangible impact on the quality of life, economic development and welfare of society.
